Print Print page     Email Email page

Investor Relations

December 2, 2008
20th Annual Piper Jaffray Health Care Conference

VIA (Nasdaq: VIAP) is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. The Company is building a pipeline of small molecule drugs that intervene directly in the chronic inflammation underlying atherosclerosis.

Read more »

Recent Releases

Nov 9, 2008
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

Nov 6, 2008
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA

View all releases »